Menu
27/08/2008
NHS Patients To Get Sight-Saving Drug
Patients in England suffering from a crippling medical condition, age-related macular degeneration (AMD) are now to get access to a potentailly sight-saving drug.
New guidance, which applies to England, Wales and Northern Ireland, now recommends Lucentis (also called ranibizumab) for treating wet AMD. It is already available in Scotland.
The National Institute for Health and Clinical Excellence (NICE) had initially said that patients should wait until they went blind in one eye – which caused an outcry.
The reaction prompted a U-turn by the NHS advisory body in December.
The announcement comes after a unique agreement between NICE and the drug's manufacturer Novartis.
Under the deal, the NHS will only fund 14 injections, at a cost of £761 per injection and Novartis will meet any more in a scheme dubbed "dose capping".
A two-year course of treatment will costs trusts between £10,700 and £18,300.
However, some primary care trusts (PCTs), which decide on funding on a local level in the NHS, have been paying for treatment ahead of the final NICE approval which prompted accusations of a postcode lottery against the NHS.
To add to the controversy, legal action was taken against PCTs which were not paying for it.
Andrew Dillon, Chief Executive of NICE said: "Lucentis is an expensive drug, costing more than £10,000 for each eye treated. But that cost needs to be balanced against the likely cost savings.
"I am genuinely sorry that it has taken us so long to get to this point. Lessons could be learned by everybody involved."
Steve Winyard, Head of Campaigns at the Royal National Institute for the Blind said "we've been waiting for this for over two years" and "it is a victory for thousands, bringing overwhelming relief to desperate people across the country".
"NICE's guidance will finally bring an end to a cruel postcode lottery. There is now nowhere left for PCTs to hide – we want the them to implement NICE guidance immediately.
"RNIB is also calling on hospitals to ensure they build capacity as a matter of urgency, so they can save the sight of patients without further delay."
Age-related macular degeneration (AMD) comes in two forms – wet and dry.
While the dry is more common, the wet type is more aggressive and is responsible for about 90% of blindness caused by the condition.
Up to 20,000 people are diagnosed with wet AMD in England.
While Lucentis will be available to patients on the NHS, NICE has not recommended another anti VEGF drug Macugen.
RNIB hopes that this drug will also be made available for patients in exceptional circumstances who for medical reasons won't be able to use Lucentis.
(DS)
New guidance, which applies to England, Wales and Northern Ireland, now recommends Lucentis (also called ranibizumab) for treating wet AMD. It is already available in Scotland.
The National Institute for Health and Clinical Excellence (NICE) had initially said that patients should wait until they went blind in one eye – which caused an outcry.
The reaction prompted a U-turn by the NHS advisory body in December.
The announcement comes after a unique agreement between NICE and the drug's manufacturer Novartis.
Under the deal, the NHS will only fund 14 injections, at a cost of £761 per injection and Novartis will meet any more in a scheme dubbed "dose capping".
A two-year course of treatment will costs trusts between £10,700 and £18,300.
However, some primary care trusts (PCTs), which decide on funding on a local level in the NHS, have been paying for treatment ahead of the final NICE approval which prompted accusations of a postcode lottery against the NHS.
To add to the controversy, legal action was taken against PCTs which were not paying for it.
Andrew Dillon, Chief Executive of NICE said: "Lucentis is an expensive drug, costing more than £10,000 for each eye treated. But that cost needs to be balanced against the likely cost savings.
"I am genuinely sorry that it has taken us so long to get to this point. Lessons could be learned by everybody involved."
Steve Winyard, Head of Campaigns at the Royal National Institute for the Blind said "we've been waiting for this for over two years" and "it is a victory for thousands, bringing overwhelming relief to desperate people across the country".
"NICE's guidance will finally bring an end to a cruel postcode lottery. There is now nowhere left for PCTs to hide – we want the them to implement NICE guidance immediately.
"RNIB is also calling on hospitals to ensure they build capacity as a matter of urgency, so they can save the sight of patients without further delay."
Age-related macular degeneration (AMD) comes in two forms – wet and dry.
While the dry is more common, the wet type is more aggressive and is responsible for about 90% of blindness caused by the condition.
Up to 20,000 people are diagnosed with wet AMD in England.
While Lucentis will be available to patients on the NHS, NICE has not recommended another anti VEGF drug Macugen.
RNIB hopes that this drug will also be made available for patients in exceptional circumstances who for medical reasons won't be able to use Lucentis.
(DS)
Related UK National News Stories
Click here for the latest headlines.
26 March 2007
'Postcode lottery' remains in NHS dental care
There are "huge regional variations" in NHS dental care in England, consumer organisation Which? has warned in new research. The survey of 466 dentistry practices - which comes a year after the start of new NHS dentists' contract in England - found that just over a third (36%) are taking on any new NHS patients.
'Postcode lottery' remains in NHS dental care
There are "huge regional variations" in NHS dental care in England, consumer organisation Which? has warned in new research. The survey of 466 dentistry practices - which comes a year after the start of new NHS dentists' contract in England - found that just over a third (36%) are taking on any new NHS patients.
23 April 2014
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.
24 August 2010
Cancer Drug Too Expensive For NHS
Campaigners say they have been let down after a health watchdog refused a life saving drug for bowel cancer to be available on the NHS. The National Institute for Health and Clinical Excellence (NICE) rejected Roche's drug Avastin (bevacizumab), which can help patients with advanced bowel cancer, claiming it was too expensive.
Cancer Drug Too Expensive For NHS
Campaigners say they have been let down after a health watchdog refused a life saving drug for bowel cancer to be available on the NHS. The National Institute for Health and Clinical Excellence (NICE) rejected Roche's drug Avastin (bevacizumab), which can help patients with advanced bowel cancer, claiming it was too expensive.
04 February 2009
Kidney Cancer Drug Given Green Light
A drug, which prolongs the life of kidney cancer sufferers, has been given the go-ahead for patients in England and Northern Ireland, in a U-turn move. The National Institute for Health and Clinical Excellence (NICE) - the NHS drugs watchdog - published revised guidance on the drug Sutent (sunitinib).
Kidney Cancer Drug Given Green Light
A drug, which prolongs the life of kidney cancer sufferers, has been given the go-ahead for patients in England and Northern Ireland, in a U-turn move. The National Institute for Health and Clinical Excellence (NICE) - the NHS drugs watchdog - published revised guidance on the drug Sutent (sunitinib).
08 August 2014
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
